Source link : https://www.newshealth.biz/health-news/ema-supports-expanding-use-of-ofev-to-pediatric-ilds/
The European Medicines Agency (EMA) has recommended extending the use of Ofev (nintedanib) to include treating progressive fibrosing interstitial lung diseases (ILDs) in children and adolescents aged 6 years or older. Varying Ofev’s marketing authorization would mark the first approved therapy in Europe for these respiratory conditions in children. Fibrosing ILDs encompass a group of […]
Author : News Health
Publish date : 2024-12-13 16:19:52
Copyright for syndicated content belongs to the linked Source.